In an effort to find an effective antiviral drug against SARS-CoV-2. Calibr, the drug development division of Scripps Research, is leveraging a unique resource—the ReFRAME drug collection. The ReFRAME drug collection comprises over 14,000 compounds that have been approved by the FDA for other diseases. A medicine identified from this resource could be rapidly repurposed.
Comments are closed.